Ma Y H, Landis C, Tchao N, Wang J, Rodd G, Hanahan D, Bourne H R, Grodsky G M
Department of Pharmacology, University of California, San Francisco 94143.
Endocrinology. 1994 Jan;134(1):42-7. doi: 10.1210/endo.134.1.7506212.
To evaluate the effect of chronically elevated adenylyl cyclase, we targeted the expression of a constitutively active mutant alpha-subunit (alpha s+) of Gs to the insulin-producing pancreatic beta-cells of transgenic mice. As assessed by the polymerase chain reaction, expression of alpha s+ mRNA was restricted to the transgenic pancreas. Histological analysis by light microscopy and immunohistochemistry for insulin, glucagon, and somatostatin appeared normal in transgenic islets. Pancreatic insulin content was quantitatively the same for alpha s+ transgenic and control mice. Comparisons of glucose homeostasis, insulin secretion, and islet cAMP revealed the expected differences between alpha s+ transgenic and control mice; in every case, however, responses to glucose alone were normal, and the differences were observed only when measurements were performed in the presence of isobutylmethylxanthine (IBMX), an inhibitor of cAMP phosphodiesterase. 1) In vivo, ip glucose tolerance was normal in alpha s+ transgenics; when ip glucose was preceded by administration of IBMX, the rise in blood glucose was approximately 33% less in the transgenic than in the control mice. 2) Insulin secretion from the perfused pancreas stimulated sequentially with 11 and 22 mM glucose caused characteristic first and second phase insulin release that did not differ between transgenic and control pancreases. IBMX increased biphasic insulin release from all pancreases, but caused a 2-fold greater than normal release from the transgenics. 3) Similarly, batch-incubated alpha s+ and control islets secreted equivalent amounts of insulin in the presence of glucose (22 mM) alone, whereas the combination of glucose plus IBMX was twice as effective on alpha s+ islets. 4) Islet cAMP levels paralleled insulin secretion; in the presence of IBMX, but not glucose alone, cAMP was increased 2-fold more in alpha s+ vs. control islets. We conclude that expression of constitutively active alpha s mutant in pancreatic beta-cells of transgenic mice is functionally effective, causing the physiological phenotype of increased islet cAMP and insulin secretion. However, these changes are uncovered only in the presence of IBMX; without IBMX, glucose homeostasis and islet function appear normal. This normalization, or counterregulation, of cAMP synthesis presumably is accomplished by a compensatory increase in cAMP degradation, possibly via increased activity of cAMP phosphodiesterase.
为评估腺苷酸环化酶长期升高的影响,我们将组成型活性Gsα亚基突变体(αs+)的表达靶向于转基因小鼠的胰岛素分泌胰腺β细胞。通过聚合酶链反应评估,αs+ mRNA的表达仅限于转基因胰腺。转基因胰岛的光镜组织学分析以及胰岛素、胰高血糖素和生长抑素的免疫组织化学分析均显示正常。αs+转基因小鼠和对照小鼠的胰腺胰岛素含量在数量上相同。对葡萄糖稳态、胰岛素分泌和胰岛cAMP的比较揭示了αs+转基因小鼠和对照小鼠之间的预期差异;然而,在每种情况下,单独对葡萄糖的反应都是正常的,差异仅在存在环磷酸腺苷磷酸二酯酶抑制剂异丁基甲基黄嘌呤(IBMX)的情况下进行测量时才观察到。1)在体内,αs+转基因小鼠的腹腔注射葡萄糖耐量正常;当腹腔注射葡萄糖前先给予IBMX时,转基因小鼠的血糖升高比对照小鼠低约33%。2)用11和22 mM葡萄糖顺序刺激灌注胰腺分泌胰岛素,转基因胰腺和对照胰腺均出现特征性的第一相和第二相胰岛素释放,两者无差异。IBMX增加了所有胰腺的双相胰岛素释放,但转基因胰腺的释放比正常情况高2倍。3)同样,在仅存在葡萄糖(22 mM)的情况下,批量培养的αs+胰岛和对照胰岛分泌等量的胰岛素,而葡萄糖加IBMX的组合对αs+胰岛的作用是对照胰岛的两倍。4)胰岛cAMP水平与胰岛素分泌平行;在存在IBMX而非仅存在葡萄糖的情况下,αs+胰岛中的cAMP比对照胰岛增加2倍以上。我们得出结论,在转基因小鼠的胰腺β细胞中组成型活性αs突变体的表达在功能上是有效的,导致胰岛cAMP增加和胰岛素分泌的生理表型。然而,这些变化仅在存在IBMX的情况下才会显现;没有IBMX时,葡萄糖稳态和胰岛功能看起来正常。cAMP合成的这种正常化或反调节可能是通过cAMP降解的代偿性增加来实现的,可能是通过cAMP磷酸二酯酶活性的增加。